Sydney, Australia and New Canaan, Connecticut.

 An
View full article

European symposium focuses on phenoxodiol as an investigational drug for ovarian cancer management
Tuesday, 30 October 2007
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Chairman's address to the 2007 Annual General Meeting.
Friday, 26 October 2007

It is with pleasure that I present to you, our valued shareholders, my
View full article

Presentations made at the 2007 AGM can be listened to online.
Friday, 26 October 2007
Listen to the Annual General Meeting presentations online. View full article

Novogen announces collaboration agreement to bring cosmetic products to market
Friday, 26 October 2007
NEW CANAAN, CT and SYDNEY, Australia, 25 October, 2007 -- Novogen Limited
View full article

Novogen's NV-128 induces novel mode of cell death in cancer cells
Thursday, 25 October 2007
(San Francisco – 24 October) - Laboratory studies presented late
View full article

European symposium on phenoxodiol as an investigational drug for ovarian cancer management
Tuesday, 23 October 2007
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Yale Cancer Center sponsors study of phenoxodiol for prostate cancer
Tuesday, 23 October 2007
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Novogen sells Wyong holding
Wednesday, 10 October 2007
Novogen today advises that it has sold its land and buildings at Wyong
View full article

Marshall Edwards, Inc., to present at BIO Investor Forum 2007
Wednesday, 3 October 2007
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Interview with Novogen's CEO Mr Christopher Naughton
Thursday, 30 August 2007
Listen to this interview online. View full article

First patient enrolled in Europe in Ovature Phase III ovarian cancer trial
Monday, 27 August 2007
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Newly published research indicates the potential of phenoxodiol to protect against Neuropathy
Monday, 13 August 2007
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

An interview with Mr Christopher Naughton, CEO of Novogen Limited
Tuesday, 7 August 2007
Listen to this interview online. View full article

Marshall Edwards, Inc., raises US$16.4m in private equity financing
Monday, 6 August 2007
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Investigational anti-inflamatory drug produces promising results in animal studies
Monday, 30 July 2007
A new experimental anti-inflammatory drug has produced promising results
View full article

Clarification regarding Dr Kelly
Friday, 13 July 2007
Media coverage yesterday referred to the Australian Taxation Office
View full article

Novogen reaches settlement with Chattem, Inc., on isoflavone patent infringement case
Tuesday, 26 June 2007
Sydney Australia., 26 June, 2007 - Novogen Limited (ASX: NRT - Nasdaq:
View full article

Interview with Christopher Naughton, Managing Director, Novogen Limited
Tuesday, 5 June 2007
Listen to this interview online. View full article

Marshall Edwards Ovature trial enrols first US patient
Friday, 1 June 2007
PHASE III TRIAL FOR PHENOXODIOL TO RECRUIT NEARLY 500 PATIENTS WITH
View full article

Novogen consumer products facility
Friday, 4 May 2007
Following an extensive review of capacity, quality, and technical
View full article

New research shows phenoxodiol targeting cancer protein, causing cancer cell death
Wednesday, 2 May 2007
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Novogen Limited's US patent issued for phenoxodiol
Monday, 16 April 2007
Novogen Limited (Nasdaq: NVGN; ASX:NRT) advises that it has been granted
View full article

Marshall Edwards, Inc., appoints a new Director
Thursday, 29 March 2007
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

An interview with Novogen's CEO Mr Christopher Naughton
Tuesday, 6 March 2007
Listen to this interview online. View full article

Novogen announcement
Tuesday, 27 February 2007
Novogen Limited (ASX : NRT; Nasdaq : NVGN) reports that its US
View full article

Novogen Director resigns
Wednesday, 31 January 2007
31 January, 2007 The Announcements Platform Australian Stock
View full article

Novogen and Sante Naturelle (Canada) enter patent licence agreement
Thursday, 18 January 2007
STAMFORD, Conn., January 17, 2007 - Novogen Limited (Nasdaq: NVGN), the
View full article

Novogen Limited's patent advance for phenoxodiol
Monday, 11 December 2006
Novogen Limited (ASX:NRT; Nasdaq:NVGN) advises that it has recently
View full article

Marshall Edwards announces appointment of Professor Bryan Williams as Chairman
Tuesday, 28 November 2006
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Marshall Edwards announces first patient in Phase III Ovarian cancer trial
Friday, 24 November 2006
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Marshall Edwards Inc appoints JPMorgan exclusive financial advisor
Monday, 30 October 2006
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Novogen Limited announcement
Monday, 30 October 2006
NOVOGEN ANNOUNCEMENT Novogen Limited advises the market that Dr Graham
View full article

Novogen Limited to present at the Rodman & Renshaw Conference
Monday, 30 October 2006
NOVOGEN LIMITED TO PRESENT AT THE RODMAN & RENSHAW 8TH ANNUAL HEALTHCARE
View full article

Marshall Edwards Inc to present at Rodman & Renshaw Conference
Monday, 30 October 2006
MARSHALL EDWARDS INC TO PRESENT AT THE RODMAN & RENSHAW 8TH ANNUAL
View full article

Chairman's address to the 2006 Annual General Meeting
Friday, 27 October 2006
27 October, 2006 I would like to provide our shareholders a broad
View full article

Novogen licences US rights to Promensil and Trinovin brands to Natrol
Monday, 23 October 2006
CHATSWORTH, Calif. & STAMFORD, Conn., October 23, 2006 – Natrol, Inc.
View full article

Marshall Edwards Inc presentation to the UBS Global Life Sciences Conference now available
Tuesday, 26 September 2006
The Marshall Edwards Inc presentation to the UBS Global Life Sciences
View full article

Marshall Edwards Inc to Present at the UBS Global Life Sciences Conference.
Tuesday, 19 September 2006
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Early study provides evidence that investigational drug phenoxodiol targets prostate cancer protein.
Monday, 18 September 2006
Novogen Limited's subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and
View full article

Investigational drug targeting inflammatory bowel disease enters second human clinical trial
Monday, 7 August 2006
Novogen Limited’s investigational anti-inflammatory compound NV-52, is
View full article

Marshall Edwards raises a total of $18m plus $15m equity line of credit
Wednesday, 12 July 2006
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Marshall Edwards raises $14m in private equity financing
Wednesday, 12 July 2006
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Austrian Court upholds Novogen Patent for red clover isoflavones
Thursday, 15 June 2006
The Vienna Commercial Court has found that Novogen’s isoflavone invention
View full article

Novogen renegotiates phenoxodiol Licence Agreement
Wednesday, 7 June 2006
Novogen Limited (ASX: Novogen - Nasdaq: NVGN) has renegotiated with
View full article

Novogen Limited appoints new Director
Thursday, 25 May 2006
Novogen Limited (ASX: NRT Nasdaq: NVGN) has appointed Professor Alan
View full article

Interview with Novogen's CEO Mr Christopher Naughton
Tuesday, 23 May 2006
Listen to this interview online. View full article

Marshall Edwards achieves special protocol assessment and agreement with FDA
Tuesday, 16 May 2006
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Marshall Edwards, Inc. licenses two anti-cancer compounds from Novogen Limited
Monday, 15 May 2006
(Washington DC; and Sydney Australia) - Novogen Limited and Marshall
View full article

Novogen's subsidiary Marshall Edwards, Inc., presenting in New York
Friday, 31 March 2006
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Yale researchers find phenoxodiol restores sensitivity to chemo in some women with ovarian cancer
Wednesday, 29 March 2006
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Appointment of new Governor creates board vacancy at Marshall Edwards, Inc.
Wednesday, 29 March 2006
Novogen Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has
View full article

Australian Stock Exchange - price query
Wednesday, 22 March 2006
22 March 2006 Ms Kim-Ly Nguyen Senior Adviser, Issuers
View full article

Positive data from Novogen inflammatory bowel disease drug phase I clinical trial
Thursday, 2 March 2006
A recently completed Phase 1 clinical trial of a new drug to treat
View full article

Novogen advances clinical trial programs and retains solid cash position
Friday, 24 February 2006
Pharmaceutical company, Novogen Limited (ASX: NRT, NASDAQ: NVGN), has
View full article

Novogen appeals injunction decision in the Netherlands
Wednesday, 18 January 2006
(Stamford, Conn., Sydney, Australia) January 18, 2006. Novogen Limited
View full article

New CEO and President appointed for Glycotex, Inc.
Wednesday, 18 January 2006
Pharmaceutical company, Novogen Limited, announced today that its US
View full article

Glycotex Inc., postpones proposed Initial Public Offering of its common stock units
Thursday, 12 January 2006
Pharmaceutical company Novogen Limited announced today that Glycotex,
View full article

Review of the Remuneration Report
Friday, 16 December 2005
Prior to the vote being taken at its Annual General Meeting the Chairman
View full article

Novogen Subsidiary MEI announces joint trial with Sanofi-Aventis
Tuesday, 29 November 2005
NEW CLINICAL STUDY OF PHENOXODIOL AS CHEMO-SENSITIZER FOR DOCETAXEL IN
View full article

Novogen's subsidiary, Marshall Edwards, Inc., announces cervical cancer trial results
Friday, 18 November 2005
Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and
View full article

Novogen's subsidiary, Marshall Edwards, Inc., announces prostate cancer trial results
Friday, 18 November 2005
Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and
View full article

Novogen announcement
Friday, 4 November 2005
At its Annual General Meeting held on 28 October 2005, the Chairman
View full article

Letter to shareholders from the Chairman of Novogen Limited
Thursday, 3 November 2005
3 November 2005 Dear Novogen Shareholder Novogen Limited
View full article

Chairman's address to the Annual General Meeting - 2005
Friday, 28 October 2005
Chairman’s Address to the Annual General Meeting of Novogen
View full article

Novogen's subsidiary Marshall Edwards, Inc., announces researcher reports on phenoxodiol
Monday, 24 October 2005
Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and
View full article

Novogen drug reduces cardiovascular risk in human clinical study
Wednesday, 14 September 2005
A new cardiovascular drug developed by pharmaceutical company Novogen
View full article

Novogen announces its intention to list Glycotex, Inc., on the Nasdaq National Market
Tuesday, 13 September 2005
Pharmaceutical company Novogen Limited announced today that Glycotex,
View full article

Novogen announces development and expansion of US subsidiary companies
Friday, 2 September 2005
Novogen Limited (NASDAQ: NVGN; ASX: NRT) today announced the expansion
View full article

Novogen sales up, clinical trial results emerging
Friday, 26 August 2005
Pharmaceutical company Novogen Limited (ASX:NRT, NASDAQ:NVGN), has ended
View full article

Australian product promotes healing in venous stasis ulcers
Monday, 11 July 2005
Novogen today announced the results of a Phase II clinical trial of its
View full article

Novogen drug for inflamatory bowel disease enters phase I clinical trial
Monday, 4 July 2005
A new drug for the management of inflammatory bowel disease is to enter
View full article

Novogen receives three granted patents in Australia covering isoflavone health
Monday, 27 June 2005
Novogen Limited has received the grant of three health supplement patents
View full article

Novogen's subsidiary, Marshall Edwards, Inc., announces preliminary results
Tuesday, 10 May 2005
Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and
View full article

Novogen US subsidiary, Glycotex Inc., settles a private capital raising
Thursday, 14 April 2005
The US company, Glycotex Inc., has placed 10% of its stock with a US
View full article

Novogen's subsidiary, Marshall Edwards, Inc., announces expedited pivotal trial
Monday, 7 March 2005
Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and
View full article

Novogen sales up, significant advances with clinical trial program
Friday, 25 February 2005
Half year results for pharmaceutical company, Novogen Limited (ASX: NRT,
View full article

Novogen Limited appoints new Director
Friday, 25 February 2005
Listed pharmaceutical company, Novogen Limited (ASX: NRT Nasdaq: NVGN)
View full article

Novogen's subsidiary, Marshall Edwards, Inc., granted FDA fast track for oral phenoxodiol
Thursday, 27 January 2005
(Washington, DC – January 26, 2005) Marshall Edwards, Inc., (Nasdaq: MSHL
View full article

Novogen subsidiary, Marshall Edwards, Inc., announces phenoxodiol reverses chemo-sensitivity
Tuesday, 25 January 2005
WASHINGTON, D.C. January 24, 2005 –The investigational anti-cancer drug,
View full article

Novogen reaches settlement with GNC on isoflavone patent infringement case
Tuesday, 18 January 2005
STAMFORD, CT., January 18, 2005 - Novogen Limited (Nasdaq: NVGN), the
View full article

Novogen receives $A1.1 million royalty payment from Solae LLC
Monday, 17 January 2005
Pharmaceutical company, Novogen Limited, has received its latest
View full article

Novogen Subsidiary, Glycotex Inc, shareholder letter
Thursday, 2 December 2004
Dear Shareholder Clinical trial update. This report is to provide a
View full article

Novogen's subsidiary, Marshall Edwards, Inc., announces phenoxodiol slows disease progression
Tuesday, 23 November 2004
RESEARCHERS REPORT THAT ORAL PHENOXODIOL SLOWS DISEASE PROGRESSION IN
View full article

Novogen's subsidiary, Glycotex Inc., receives additional capital for development of Glucoprime
Monday, 22 November 2004
Novogen Limited (ASX: NRT – Nasdaq: NVGN) today announced that Glycotex,
View full article

Novogen's subsidiary, Marshall Edwards, Inc., granted FDA fast track designation for phenoxodiol
Friday, 5 November 2004
Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and
View full article

Novogen cancels options
Thursday, 4 November 2004
By agreement with the two Directors concerned the Company has cancelled
View full article

Chairman's address to the 2004 Annual General Meeting
Friday, 22 October 2004
Chairman's address to the 2004 Annual General Meeting. Good morning
View full article

Novogen cash reserves support clinical development of drug program
Thursday, 26 August 2004
Pharmaceutical company Novogen Limited (ASX:NRT, NASDAQ:NVGN), continues
View full article

Novogen cardiovascular drug enters second human clinical trial
Tuesday, 6 July 2004
Pharmaceutical company Novogen Limited is commencing a second human
View full article

Novogen's subsidiary, Marshall Edwards, Inc., names second ovarian cancer trial site for phenoxodiol
Monday, 14 June 2004
Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and
View full article

Newsletter 06.04 now available
Wednesday, 26 May 2004
The latest newsletter is available on the Novogen website - select "News"
View full article

Novogen Patent granted in Canada
Thursday, 20 May 2004
Pharmaceutical company, Novogen, has been granted patent coverage over
View full article

The University of Sydney honours Marshall Edwards, Inc., Chairman
Monday, 17 May 2004
Novogen Limited’s subsidiary, Marshall Edwards, Inc., (LSE AIM: MSH and
View full article

Novogen's second anti-cancer drug enters human clinical trials
Wednesday, 12 May 2004
(Sydney Australia) - Novogen has commenced a human clinical trial of a
View full article

Novogen wins $10 million Australian Government funding for pharmaceutical development
Monday, 26 April 2004
The Australian Government’s Department of Industry has approved ASX
View full article

Novogen's subsidiary, Marshall Edwards, Inc., confirms new Yale trial
Wednesday, 21 April 2004
Novogen Limited’s subsidiary, Marshall Edwards, Inc., (LSE AIM: MSH and
View full article

Novogen's subsidiary, Marshall Edwards, Inc., confirms 4 studies at AACR
Wednesday, 31 March 2004
Investigational anti-cancer drug phenoxodiol produces response and
View full article

Novogen's subsidiary, Marshall Edwards, Inc., confirms the 4 abstracts to be presented at AACR
Friday, 26 March 2004
Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and
View full article

Novogen's subsidiary, Marshall Edwards, Inc., commences renal cancer human trial.
Monday, 8 March 2004
(Washington, DC and Sydney, Australia) Marshall Edwards, Inc. has
View full article

Novogen's subsidiary, Marshall Edwards, Inc., commences clinical trial in cervical cancer at Yale
Sunday, 22 February 2004
Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and
View full article

Novogen builds cash reserves, performance steady, half year sales down
Friday, 20 February 2004
Half year results for pharmaceutical company, Novogen Limited (ASX: NRT,
View full article

Novogen's subsidiary, Marshall Edwards, Inc., announces Yale trial results
Tuesday, 10 February 2004
Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE AIM: MSH and
View full article

Novogen's subsidiary, Marshall Edwards, Inc., announces pricing of Initial Public Offering.
Friday, 19 December 2003
Novogen Limited’s subsidiary, Marshall Edwards, Inc. (LSE_AIM: MSH and
View full article

Novogen's Marshall Edwards, Inc. subsidiary receives US$10.1m from warrants exercised
Wednesday, 3 December 2003
(Sydney, Australia / Stamford, Connecticut, US 3 December 2003) Novogen
View full article

Novogen gains new US health supplement patent and receives milestone payment
Monday, 1 December 2003
Novogen has been granted the US patent covering health supplements based
View full article

Novogen granted US patent covering phenoxodiol for cancer treatment
Wednesday, 19 November 2003
Pharmaceutical company Novogen, has been granted the US patent covering
View full article

Chairman's address to the Annual General Meeting
Friday, 24 October 2003
Novogen AGM 2003 Chairman’s address 1. Company achievements over the
View full article

Novogen Subsidiary, MEI, announces intention to list on the Nasdaq SmallCap market
Friday, 26 September 2003
Novogen Limited’s subsidiary, Marshall Edwards Inc. (LSE-AIM: MSH), has
View full article

Letter to Shareholders from the Managing Director
Wednesday, 24 September 2003
Dear Shareholders, It is a pleasure to report the results for the
View full article

Novogen Limited appoints new Director
Monday, 15 September 2003
ASX and NASDAQ listed pharmaceutical company, Novogen Limited, has
View full article

Novogen retains cash, improved performance and sales steady
Friday, 29 August 2003
Pharmaceutical company Novogen Limited (ASX:NRT, NASDAQ:NVGN), has
View full article

Novogen awarded US patent for isoflovones to treat estrogen dependent disease
Monday, 18 August 2003
Pharmaceutical company, Novogen Limited, has been granted a patent in the
View full article

Novogen subsidiary, MEI, announces appointment of Director
Monday, 4 August 2003
Novogen Limited’s subsidiary, Marshall Edwards Inc. (LSE-AIM: MSH), has
View full article

Isoflavone study results conflict with previous data
Thursday, 10 July 2003
A study published in the latest edition of the US Journal of the American
View full article

IND approval from FDA for phenoxodiol oral form plus an additional trial at Yale
Tuesday, 17 June 2003
Novogen Limited’s subsidiary, Marshall Edwards Inc. (LSE-AIM: MSH), has
View full article

Novogen licensee files patent infringement suit against ADM and Amerifit
Monday, 9 June 2003
Novogen Limited has been advised that the licensee of its soy related
View full article

phenoxodiol combined with small doses of chemotherapy reduces ovarian cancer tumour mass by 75 %
Tuesday, 3 June 2003
Novogen Limited’s subsidiary, Marshall Edwards Inc. (LSE-AIM: MSH), has
View full article

Novogen awarded US patent for isoflavones to treat menopause & PMS
Tuesday, 20 May 2003
Pharmaceutical company Novogen Limited has been granted a patent in the
View full article

Novogen group commences phase II glucan trial for skin ulcer repair
Thursday, 8 May 2003
Pharmaceutical company, Novogen Limited, is commencing a Phase II human
View full article

Oncogene publishes phenoxodiol data
Thursday, 1 May 2003
Yale researchers find phenoxodiol overwhelmingly effective for treating
View full article

Skin cancer phase 2 trial approved for oral phenoxodiol at Royal North Shore Hospital
Tuesday, 8 April 2003
Pharmaceutical company, Novogen Limited, through its associated company
View full article

Yale researchers report phenoxodiol kills ovarian cancer cells
Tuesday, 1 April 2003
The Yale School of Medicine announcement is: “New Haven, Conn. – Yale
View full article

Novogen announces that Marshall Edwards Inc is on schedule with its phase 2 anti-cancer program
Monday, 3 March 2003
Novogen Limited’s subsidiary, Marshall Edwards Inc. (LSE-AIM: MSH), has
View full article

Novogen reduces loss, expands drug trials and increases sales
Monday, 3 March 2003
Pharmaceutical company, Novogen Limited is positioning itself for the
View full article

Novogen granted US patent covering soy hypocotyls, a natural source of isoflavones
Thursday, 16 January 2003
Novogen Limited has been issued the patent in the US for human dietary
View full article

Australain Patent Granted to Novogen covering its skin repair compound NV-07α
Monday, 13 January 2003
The Australian patent has been granted to Novogen for its topical skin
View full article

Novogen receives$A2.3m royalty payment from DuPont Protein Technologies
Monday, 6 January 2003
Pharmaceutical company, Novogen Limited, today announced receipt of a
View full article